Q-omics provides the consensus-scored DEFB125 profile across patient tissues and cancer cell-line models. DEFB125 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DEFB125 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, DEFB125 RNA expression shows 6,103 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, and STAD as cancer lineages where DEFB125 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB125 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB125 survival associations across molecular data types. DEFB125 RNA expression shows survival associations in the most cancer types (9), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB125 RNA expression–survival associations across cancer types. High DEFB125 expression shows unfavorable associations in KIRC, KICH, ACC, THCA and COAD, but favorable associations in MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for DEFB125 RNA expression.
This table summarizes DEFB125 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB125. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB125 shows lower tumor expression in KIRC and KICH and higher tumor expression in STAD. The KIRC box plot shows higher DEFB125 RNA expression in normal versus tumor tissue (log2 FC = −0.169, t-test p = .004).
This table shows molecular features associated with DEFB125 in patient tissues and cancer cell lines. In patient samples, DEFB125 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB125 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
